Latest Regulatory News

Australia’s ANSTO has independently confirmed that Lindian Resources’ Kangankunde monazite concentrate is exempt from radioactive transport classification, simplifying export logistics and lowering downstream costs.

Tungsten Mining is pursuing a US stock exchange listing to tap into deeper capital markets and strengthen ties with US government and industry stakeholders, complementing its existing ASX listing.

Heartland Group Holdings Limited reports a robust turnaround in first-half 2026 net profit, driven by margin expansion, asset quality improvements, and strong Reverse Mortgage growth in New Zealand and Australia. The group also advances significant technology investments and benefits from eased Reserve Bank capital requirements.

Artrya Limited reported a 44% increase in its half-year loss to $10.7 million as it transitioned from development to commercial operations in the US, securing FDA clearance and signing three foundation customers. An $80 million capital raise underpins its ambitious US expansion and ongoing product development.

Australian Unity Limited reported increased revenue for the half-year ending December 2025, but earnings declined sharply due to inflationary pressures and ongoing transformation investments. The company also completed a leadership transition and strengthened its balance sheet.

NeuroScientific Biopharmaceuticals reported a $1.7 million loss for the half-year ending December 2025, driven by ongoing R&D investments. The company progressed clinical treatments for Crohn’s disease and glaucoma, alongside key leadership appointments and strategic partnerships.

Suncorp Group Limited has updated its dividend distribution details, confirming a fully franked ordinary dividend of AUD 0.17 per share payable in March 2026, with tailored currency payment options for shareholders.

Cyclopharm Limited reported a 17% revenue increase to a record $32.3 million in 2025, powered by a 226% surge in US Technegas sales. The company is accelerating its US rollout with plans for up to 300 installations in 2026, while advancing clinical trials beyond pulmonary embolism.

TPC Consolidated Limited reported a 4.1% revenue increase to $103.6 million and a 62% jump in underlying EBITDA for the half-year ended December 2025, while the proposed acquisition scheme faces regulatory hurdles.

Cleo Diagnostics reported a 53% drop in revenues and a slight increase in net loss to $1.98 million for H1 2025, while progressing its pivotal FDA clinical trial for an ovarian cancer blood test with strong regulatory and commercial milestones.

Island Pharmaceuticals reports a 213.8% increase in half-year loss to $4.81 million, driven by strategic acquisition and clinical development investments. The company advances its antiviral portfolio with Galidesivir and ISLA-101, supported by strong US regulatory engagement and a $9 million capital raise.

Immuron Limited reported a narrower half-year loss alongside record sales growth and FDA approval for its IMM-529 drug candidate, signalling promising clinical and commercial momentum.